DB:2DT

Stock Analysis Report

Executive Summary

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.

Snowflake

Fundamentals

Fair value with concerning outlook.


Similar Companies

Share Price & News

How has Amneal Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

16.4%

2DT

0.5%

DE Pharmaceuticals

2.4%

DE Market


1 Year Return

-82.2%

2DT

-3.8%

DE Pharmaceuticals

4.9%

DE Market

Return vs Industry: 2DT underperformed the German Pharmaceuticals industry which returned -3.8% over the past year.

Return vs Market: 2DT underperformed the German Market which returned 4.9% over the past year.


Shareholder returns

2DTIndustryMarket
7 Day16.4%0.5%2.4%
30 Day1.8%-1.1%2.3%
90 Day-5.8%8.2%2.7%
1 Year-82.2%-82.2%-0.5%-3.8%8.2%4.9%
3 Yearn/a30.4%15.8%18.3%8.0%
5 Yearn/a30.8%9.1%44.2%24.6%

Price Volatility Vs. Market

How volatile is Amneal Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Amneal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2DT (€2.84) is trading below our estimate of fair value (€12.02)

Significantly Below Fair Value: 2DT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2DT is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 2DT is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2DT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2DT is good value based on its PB Ratio (0.8x) compared to the DE Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is Amneal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

-21.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2DT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2DT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2DT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2DT's revenue (3.3% per year) is forecast to grow slower than the German market (5% per year).

High Growth Revenue: 2DT's revenue (3.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2DT's Return on Equity is forecast to be high in 3 years time (30.7%)


Next Steps

Past Performance

How has Amneal Pharmaceuticals performed over the past 5 years?

-39.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 2DT is unprofitable, and losses have increased over the past 5 years at a rate of -39.8% per year.

Accelerating Growth: Unable to compare 2DT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2DT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).


Return on Equity

High ROE: 2DT has a negative Return on Equity (-23.77%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: 2DT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 2DT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Amneal Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 2DT's short term assets ($1.2B) exceeds its short term liabilities ($546.2M)

Long Term Liabilities: 2DT's short term assets (1.2B) do not cover its long term liabilities (3.0B)


Debt to Equity History and Analysis

Debt Level: 2DT's debt to equity ratio (352.5%) is considered high

Reducing Debt: Insufficient data to determine if 2DT's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 2DT's debt is not well covered by operating cash flow (8.9%).

Interest Coverage: 2DT is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet

Inventory Level: 2DT has a high level of physical assets or inventory.

Debt Coverage by Assets: 2DT's debt is not covered by short term assets (assets are 0.4x debt).


Next Steps

Dividend

What is Amneal Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.5%markettop25%3.8%industryaverage3.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 2DT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2DT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 2DT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2DT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 2DT is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2DT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Amneal Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

0.5yrs

Average management tenure


CEO

Chirag Patel (52yo)

0.2yrs

Tenure

US$325,000

Compensation

Mr. Chirag K. Patel serves as Co-Chief Executive Officer at Amneal Pharmaceuticals, Inc. since August 5, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as Director and served as i ...


Management Age and Tenure

0.5yrs

Average Tenure

51yo

Average Age

Experienced Management: 2DT's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Age and Tenure

1.4yrs

Average Tenure

52yo

Average Age

Experienced Board: 2DT's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: 2DT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$107,81328 Aug 19
Ted Nark
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares50,000
Max PriceUS$2.16
BuyUS$65,15720 Aug 19
Pradeep Bhadauria
EntityIndividual
Role
Chief Scientific Officer
Chief Scientific Officer
Shares30,000
Max PriceUS$2.17
BuyUS$849,94208 Aug 19
Fosun International Holdings Ltd.
EntityCompany
Shares327,000
Max PriceUS$2.60
BuyUS$171,56807 Aug 19
Andrew Boyer
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Commercial Operations
Shares66,666
Max PriceUS$2.57
BuyUS$4,462,37907 Aug 19
Fosun International Holdings Ltd.
EntityCompany
Shares1,642,300
Max PriceUS$2.72
BuyUS$52,98516 May 19
Pradeep Bhadauria
EntityIndividual
Role
Chief Scientific Officer
Chief Scientific Officer
Shares7,000
Max PriceUS$7.57
BuyUS$160,02313 May 19
Andrew Boyer
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Commercial Operations
Shares19,000
Max PriceUS$8.42
BuyUS$131,94213 May 19
Joseph Todisco
EntityIndividual
Shares15,000
Max PriceUS$8.80
BuyUS$179,51912 Mar 19
Robert Stewart
EntityIndividual
Role
Senior Key Executive
Shares17,000
Max PriceUS$10.56
BuyUS$180,27212 Mar 19
Paul Bisaro
EntityIndividual
Shares17,000
Max PriceUS$10.60
SellUS$255,57607 Mar 19
Peter Terreri
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares23,345
Max PriceUS$10.95

Ownership Breakdown


Management Team

  • Andy Boyer (53yo)

    Executive Vice President of Commercial Operations

    • Tenure: 1.7yrs
    • Compensation: US$4.29m
  • David Buchen (54yo)

    Senior VP

    • Tenure: 0.8yrs
  • Chirag Patel (52yo)

    Co-Founder

    • Tenure: 0.2yrs
    • Compensation: US$325.00k
  • Apurva Saraf

    Vice President of Global Operations & Business Development

    • Tenure: 0yrs
  • Mark Donohue

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Chintu Patel (47yo)

    Co-Founder

    • Tenure: 17.8yrs
    • Compensation: US$325.00k
  • Rob Stewart (51yo)

    • Tenure: 0.2yrs
    • Compensation: US$12.35m
  • Nikita Shah (41yo)

    Senior VP & Chief Human Resources Officer

    • Tenure: 0yrs
    • Compensation: US$1.54m
  • Todd Branning (49yo)

    CFO & Senior VP

    • Tenure: 0.8yrs
  • Pradeep Bhadauria

    Chief Scientific Officer

    • Tenure: 0.5yrs

Board Members

  • Paul Meister (66yo)

    Chairman

    • Tenure: 0.2yrs
  • J. Buchi (64yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$345.00k
  • Ted Nark (61yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$338.33k
  • Peter Terreri (61yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$346.67k
  • Chirag Patel (52yo)

    Co-Founder

    • Tenure: 0.2yrs
    • Compensation: US$325.00k
  • Chintu Patel (47yo)

    Co-Founder

    • Tenure: 17.8yrs
    • Compensation: US$325.00k
  • Kanu Patel

    Chairman & MD of Amneal Pharmaceuticals (India) Pvt Ltd

    • Tenure: 0yrs
  • Gautam Patel (46yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$331.67k
  • Jean Greene (46yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$330.00k
  • Emily Alva (44yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$335.00k

Company Information

Amneal Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amneal Pharmaceuticals, Inc.
  • Ticker: 2DT
  • Exchange: DB
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$894.292m
  • Market Cap: US$356.263m
  • Listing Market Cap: US$802.717m
  • Shares outstanding: 299.09m
  • Website: https://www.amneal.com

Number of Employees


Location

  • Amneal Pharmaceuticals, Inc.
  • 400 Crossing Boulevard
  • 3rd Floor
  • Bridgewater
  • New Jersey
  • 8807
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMRXNYSE (New York Stock Exchange)YesClass A Common SharesUSUSDMay 2018
2DTDB (Deutsche Boerse AG)YesClass A Common SharesDEEURMay 2018

Biography

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeut ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 22:32
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.